Table 1 Flow diagram of study selection. One hundred forty-five patients were assigned to either the PTEN-loss or PTEN-positive group, based on the PTEN IHC results. The PTEN-loss group had 29 patients and the PTEN-positive group had 116 patients.

From: PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma